446 results about "Bacterosira" patented technology

The invention relates to the technical field of microorganisms, and particularly discloses a fermentation method of bifidobacterium longum BBMN68 as well as a fermented product, a postbiotic and application of the fermented product. According to the method for fermenting the bifidobacterium longum BBMN68, a fermentation substrate comprises alkaline protease hydrolyzed milk and a pomelo peel extract; the hydrolysis rate of the alkaline protease hydrolyzed milk is 9-11%, and the water-soluble dietary fiber content of the shaddock peel extract is 75-80%; the mass ratio of the alkaline protease hydrolyzed milk to the shaddock peel extract is (10-15): (1-3). The content of active ingredients in the fermented product prepared by the method is high, and after the fermented product is prepared into the postbiotics to be taken, the immune function of an organism can be recovered, immune organ damage is reduced, inflammation is relieved, and intestinal flora is regulated and controlled.

The invention discloses an intestinal bacterial composition for improving a cognitive function and relieving neuroinflammation and an application of the intestinal bacterial composition, and belongs to the technical field of biomedicine and microbiology, the intestinal bacterial composition is composed of a Lachnospiraceae bacterium, a Bacteroides multiforme and a Roseburiatestinae bacterium, and the intestinal bacterial composition is prepared from the following raw materials of the following raw materials of the intestinal bacterial composition: the Lachnospiraceae bacterium, the Bacteroides multiforme and the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium and the like. Experimental research results show that a modular synergistic effect exists among the helicobacter hirsuticus, the bacteroides multiforme and the Roche enterobacter, and the pharmaceutical composition has a remarkable neuroprotective effect on a cognitive impairment mouse model and an Alzheimer disease mouse model, can improve the cognitive function and relieve neuroinflammation, and can be used for preparing a neuroprotective agent for treating the cognitive impairment mouse model and the Alzheimer disease mouse model. A new thought and method can be provided for treatment of cognitive impairment related diseases and neuroinflammation related diseases.

The invention discloses bifidobacterium longum subsp.infantis capable of promoting bone growth and a metagen thereof, and belongs to the technical field of biology. The bifidobacterium longum subsp. Infantis CCFM1445 provided by the invention can promote the increase of bone volume fraction, femoral bone trabecula thickness and far-end growth plate thickness of mammals in a growth period, reduce the levels of serum bone resorption markers I-type collagen amino-terminal peptide and tartrate-resistant acid phosphatase, improve the levels of serum bone alkaline phosphatase and parathyroid hormone, and improve the clinical application value of the bifidobacterium longum subsp. Infantis CCFM1445. And the relative abundance of the other bacteria in the intestinal flora and the levels of creatine and indole-3-lactic acid are increased. The thermally inactivated bifidobacterium longum subsp. Infantis CCFM1445 can promote the increase of the volume fraction of femoral bones and the number of bone trabecula of malnourished mice and improve the N-terminal propeptide level of serum I-type procollagen. Therefore, the medicine or health care product prepared from the bifidobacterium longum subsp. Infantis CCFM1445 can be used for assisting in regulating bone metabolism and bone mass, and has a wide market prospect.

The invention belongs to the technical field of microorganisms, and particularly relates to bifidobacterium animalis for relieving eye allergy and application of the bifidobacterium animalis. The invention provides an application of bifidobacterium animalis subsp. Lactis in preparation of a product for relieving eye allergy, the bifidobacterium animalis subsp. Lactis is Def +, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.35798. The Bifidobacterium animalis subsp. Lactis Def < + > provided by the invention can relieve the eye itching symptom, relieve red and swollen eyelids, reduce conjunctiva and cornea injury, relieve eye discomfort, relieve globular conjunctivitis cell infiltration, improve corneal epithelium thickening lesion, improve the anti-inflammatory ability and improve allergic conjunctivitis, keratitis and blepharitis marginata in a targeted manner. The eye drops are high in safety and resistant to gastrointestinal fluid, and a safe and long-acting scheme is provided for eye allergic diseases.

The invention discloses an application of an antibacterial peptide and an application of the antibacterial peptide in preparation of antibacterial drugs for treating carbapenem-resistant pseudomonas aeruginosa, klebsiella pneumoniae (ATCC700603), escherichia coli (ATCC25922), staphylococcus aureus and methicillin-resistant staphylococcus aureus, the antibacterial peptide is characterized in that the sequence is w-r-r-w-k-r-w-w-r-r, and the sequence is shown in the description. All amino acids are D-type amino acids; the antibacterial peptide can be used as an antibacterial substance in wash supplies, food preservative additives, medical consumable antibacterial agents and cosmetics, can be synthesized through an Fmoc solid-phase chemical method, and is low in synthesis difficulty and good in in-vivo antibacterial activity. Particularly, the antibacterial peptide has broad-spectrum killing activity against carbapenem pseudomonas aeruginosa, klebsiella pneumoniae (ATCC700603), escherichia coli (ATCC25922), staphylococcus aureus and methicillin-resistant staphylococcus aureus, the cell survival rate of the antibacterial peptide within the range of medium and low concentration (2 mu g / mL-32 mu g / mL) reaches half or more, the toxicity is small, the toxicity is almost avoided, the operability is high, and the antibacterial peptide can be widely applied to the field of medical application. The cost is low.

The invention relates to the technical field of microorganisms, in particular to bifidobacterium bifidum BGLP1 capable of regulating sugar digestion and producing GLP-1 at high yield and application of the bifidobacterium bifidum BGLP1. The preservation number of the bifidobacterium bifidum BGLP1 is CGMCC (China General Microbiological Culture Collection Center) No.35718, and the bifidobacterium bifidum BGLP1 can be used for preparing the feed additive. The strain has the capability of inhibiting alpha-glucosidase and alpha-amylase; sTC-1 cells are stimulated to secrete GLP-1, and the blood glucose reducing pathway capacity of the intestinal tract is activated; the activity of pancreatic lipase is obviously inhibited, and the dietary fat absorption capability can be effectively reduced; redundant cane sugar is converted into exopolysaccharide, so that the probiotic function capability is improved; the capability of converting white fat into brown fat is promoted; macrophages are activated, and the body immune function is improved. In addition, the bifidobacterium bifidum BGLP1 also has relatively strong intestinal colonization ability, has good tolerance in artificial gastric juice and artificial intestinal juice, and can smoothly reach the intestinal tract of a human body.

The invention relates to a brand-new microbial natural metabolite, namely Fcl-8, which is derived from a fermentation solution of Xenorhabdius budapestensis XBD8, and is characterized in that the Fcl-8 is a new microbial natural metabolite, namely Fcl-8, which is derived from the fermentation solution of the Xenorhabdius budapestensis XBD8. The purified Fcl-8 is a snow white flocculent crystal and is very easy to dissolve in water, and the solid state of the purified Fcl-8 is as shown in Figure 1. The chemical structural formula of the Fcl-8 is as shown in a figure 2, the chemical formula is C57H102N14O12, the molecular weight is 1175.78744, and the typical secondary mass spectrum information of the Fcl-8 is as shown in a figure 3. The Fcl-8 is derived from a microbial natural metabolite, is novel in structure and high in biological activity, and has very high potential to be developed into a novel biopesticide.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Mh-GC21 as well as a precursor and application thereof. The amino acid sequence of the antibacterial peptide Mh-GC21 provided by the invention is as shown in SEQ ID NO.1, and two cysteines are oxidized to form a pair of intermolecular disulfide bonds; the C tail end of the antibacterial peptide Mh-GC21 is subjected to amidation modification. The antibacterial peptide Mh-GC21 provided by the invention is from microhyla microcarpa, has broad-spectrum antibacterial activity, has relatively good antibacterial and bactericidal effects on standard strains of acinetobacter baumannii, escherichia coli and staphylococcus aureus and clinically sourced drug-resistant strains, and can be used for targeted destruction of cell membranes of bacteria, removal of biological membranes and inhibition of formation of the biological membranes. Moreover, the antibacterial peptide Mh-GC21 has the advantages of good stability, no hemolytic activity and cytotoxicity, and difficulty in inducing strains to generate drug resistance.

The invention relates to the technical field of microorganisms, and particularly discloses bifidobacterium adolescentis AGE17 capable of promoting growth and development of muscles and bones and application of the bifidobacterium adolescentis AGE17. The bifidobacterium adolescentis AGE17 is separated from excrement of healthy children and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.33452, and the preservation date is January 17, 2025. The bifidobacterium adolescentis AGE17 has the advantages that the bifidobacterium adolescentis AGE17 can be used for preparing the biological organic fertilizer; animal experiments prove that the bifidobacterium adolescentis strain AGE17 provided by the invention has the function of promoting muscle and skeletal development, has more obvious and prominent effects compared with a model strain bifidobacterium adolescentis ATCC15703, and has important application value in increasing the muscle strength and height of children and adolescents.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in preparation of products for prevention, treatment and / or adjuvant treatment of pneumonia. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can improve the body weight decrease trend of a pneumonia mouse and reduce the lung visceral organ index of LPS increase; the content of pro-inflammatory factors such as IL-1beta, TNF-alpha and IL-6 in serum is remarkably reduced, mRNA expression of inflammation-related genes such as COX-2, IFN-gamma and TNF-alpha in lung tissue is reduced, and dose dependence is achieved; meanwhile, alveolar structure damage and inflammatory cell infiltration of mouse lung tissue are relieved, and lung tissue pathological damage is repaired. The strain can be used as a core component for developing pneumonia prevention or adjuvant therapy related products, provides a novel microbial intervention means for pneumonia prevention and treatment, and has important application value.

Provided is a Bifidobacterium breve for improving an aging-related cognitive disorder and use thereof. The Bifidobacterium breve for improving the aging-related cognitive disorder is named Bifidobacterium breve BBr16 strain with a deposit number CGMCC No. 24471. The strain can significantly improve the aging-related cognitive disorder and can be used for preparing a product with an efficacy of preventing, improving or treating the aging-related cognitive disorder.

The invention discloses a metagen prepared from bifidobacterium adolescentis and used for promoting synthesis of host collagen, and belongs to the technical field of microorganisms and medicines. The metagen of the bifidobacterium adolescentis CCFM1386 provided by the invention has a good effect of promoting synthesis of host collagen, improves moisture and elasticity of skin, and meanwhile, can improve the antioxidant capacity of the skin and maintain the stable state of collagen. The method specifically comprises the following steps: promoting the enzyme activity of the HSF cell LH1 in vitro by a thallus lysate, and improving the content of COL I and COL III and the enzyme activity of the LH1 in vitro from a fermented supernatant; the bifidobacterium adolescentis has the advantages that the content of collagen is increased by orally taking inactivated thalli, the enzyme activity of LH1, P4H and LOX can be improved by orally taking self-fermentation supernate, the synthesis of the collagen is promoted, and the content of the collagen is increased, so that the bifidobacterium adolescentis has huge application prospects in preparation of oral medicines for promoting the synthesis of host collagen and preparation of foods, health-care products or cosmetics.

The invention belongs to the technical field of microorganisms, and discloses a riemerella anatipestifer bacteriophage PT56, a bacteriophage composition thereof and application of the riemerella anatipestifer bacteriophage PT56, the collection number of the riemerella anatipestifer bacteriophage PT56 is CGMCCNO.46492, and the riemerella anatipestifer bacteriophage PT56 is collected in China General Microbiological Culture Collection Center on May 26, 2025, and the collection number is CGMCCNO.46492. The preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The riemerella anatipestifer bacteriophage PT56 has broad-spectrum bactericidal ability on riemerella anatipestifer of different serotypes, has certain temperature stability and acid-base stability, and can be used as an active ingredient for preparing drugs, disinfectants, kits and the like for preventing and treating riemerella anatipestifer diseases. The riemerella anatipestifer disinfection solution is widely applied to poultry diseases caused by riemerella anatipestifer and disinfection and sterilization of each link in the product production and processing process, is safe to use, and effectively reduces the incidence rate and the death rate of riemerella anatipestifer diseases such as poultry infectious serositis and the like.

The invention relates to the technical field of biological medicine, and discloses bifidobacterium adolescentis YF-01 and application thereof in fermented milk. The bifidobacterium adolescentis YF-01 is separated from adult excrement and is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 20251308. Experiments prove that the bifidobacterium adolescentis YF-01 has good gastrointestinal fluid tolerance, the survival rate of the bifidobacterium adolescentis YF-01 can reach 90.1% after simulated gastric fluid treatment for 3 h, and the survival rate of the bifidobacterium adolescentis YF-01 can reach 72% after simulated intestinal fluid treatment for 4 h The strain has the self-aggregation rate of 88.83% and the hydrophobicity of 79.41%, has remarkable scavenging capacity on DPPH free radicals and hydroxyl free radicals, shows good antioxidant activity and adhesion capacity, and provides a theoretical basis for application of the strain in fermented milk. The strain and metabolites thereof can be used for preparing food, medicines or health care products capable of regulating intestinal flora and enhancing oxidation resistance, and have remarkable application potential in development of functional fermented milk products.

The invention relates to a biomarker for screening intestinal flora transplantation donors and application of the biomarker. The biomarker comprises intestinal flora and metabolites thereof, the intestinal flora comprises phylum firmicalis, bacteroides and the like, and the metabolites comprise short-chain fatty acid, tryptophan, indole, 5-hydroxytryptamine, lipopolysaccharide and the like. According to the method, the intestinal flora of different crowds is deeply analyzed, the relationship between each related index of the intestinal flora and the intestinal flora transplantation effect is studied, sufficient clinical verification is carried out, a biomarker for screening the intestinal flora transplantation donor is excavated, and a standard for judging whether the intestinal flora transplantation donor is qualified or not is established; and a new method and a new idea are provided for efficiently and accurately screening intestinal flora transplantation donors.

The invention relates to the technical field of microorganisms, in particular to a citrobacter welchii bacteriophage as well as a composition and application thereof. The name of the citrobacter werkmanii bacteriophage is RDP-CI25012, the citrobacter werkmanii bacteriophage is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms on August 25, 2025, and the preservation number of the citrobacter werkmanii bacteriophage is CGMCC (China General Microbiological Culture Collection Center) No. 46668. The composition comprises the bacteriophage. The bacteriophage or the composition is prepared in the following steps: (1) preparing a product for killing citrobacter welchii; (2) preparing a product for inhibiting citrobacter welchii; and (3) application in preparation of a product for preventing and / or treating citrobacter welchii disease caused by citrobacter welchii. The cracking rate of the phage is 80%, and the phage has an extremely high host range and a relatively wide cracking spectrum. After the bacteriophage is treated at 50 DEG C for 4 hours, the titer is still kept at 107 PFU / mL or above, and the bacteriophage has excellent thermal stability, so that a solid foundation is laid for use, storage, transportation and production processing of the bacteriophage in most practical application scenes.

The invention belongs to the technical field of biology, and particularly relates to bifidobacterium longum subsp.infantis FMBL B250020GXY for metabolizing breast milk oligosaccharide and application of the bifidobacterium longum subsp.infantis FMBL B250020GXY, the bifidobacterium longum subsp.infantis FMBL B250020GXY is preserved in China Center for Type Culture Collection on September 1, 2025, and the preservation number is CCTCC M 20251931; three kinds of breast milk oligosaccharides, namely 2 '-fucosyllactose (2'-FL), lactose-N-neotetraose (LNnT) and lactose-N-tetraose (LNT), can be metabolized; plant source carbohydrates such as fructo-oligosaccharide and synanthrin can be metabolized; the compound has a relatively strong capability of removing DPPH and ABTS free radicals; a good inhibition effect is achieved on common pathogenic bacteria; good tolerance to acid and cholate is achieved; the strain is sensitive to gentamicin, streptomycin, tetracycline, chloramphenicol and vancomycin; the compound can be used for preparing antioxidant products, medicines for inhibiting pathogenic bacteria, infant foods and fermented foods, and has a wide application prospect.

The invention discloses a novel bifidobacterium infantis strain and application of extracellular products of the novel bifidobacterium infantis strain in delaying skin aging and regulating skin micro-ecology, and bifidobacterium infantis is bifidobacterium infantis BSJM24L007 which is preserved in the China General Microbiological Culture Collection Center (CGMCC for short) and has the preservation number of CGMCC No.33258. The invention further discloses a preparation method of the novel bifidobacterium infantis strain and the application of the extracellular products of the novel bifidobacterium infantis strain. The bifidobacterium infantis extracellular product prepared by the invention has an ideal effect of delaying skin aging, enables the skin to be more compact and elastic, reduces the generation of wrinkles and maintains normal metabolism of the skin, has relatively high safety, can effectively reduce the skin infection problem caused by staphylococcus aureus and propionibacterium acnes, and has a good application prospect. Skin infection and inflammation are reduced, skin health is promoted, and skin micro-ecological balance is maintained. The requirements of a modern skin external preparation on functionality and safety are met.

The invention discloses a corynebacterium glutamicum engineering strain produced by L-glutamine as well as a construction method and application of the corynebacterium glutamicum engineering strain. The corynebacterium glutamicum engineering strain is prepared by integrating a glutamine synthase encoding gene glnA which is sourced from saccharomyces cerevisiae and has a tyrosine residue mutation at the 99th site on the surface and an sRNA-MicC-EcHfq regulation module of a targeted adenylyltransferase gene glnE into a vector plasmid; the method comprises the following steps: constructing a recombinant plasmid for removing adenosine acylation of glutamine synthase; and transferring the recombinant plasmid into corynebacterium glutamicum of which the odhA gene expression is controlled by a growth stage specific promoter Pcg2705, so as to obtain a corynebacterium glutamicum engineering strain for producing L-glutamine. According to the invention, through multi-gene synergistic modification and space-time metabolic flux optimization, the problem of'growth-synthesis' tradeoff in the prior art is solved, the fermentation efficiency is improved, the fermentation process is simple, and the application prospect is good.

The present invention provides a compound of Formula (I), which can be used to prepare a composition for losing weight and improving gut microbiota composition. The invention also provides a composition comprising an effective amount of the compound, which has the ability to increase the abundance of Bacteroidales, thereby reducing the ratio of Firmicutes to Bacteroidetes, and can increase the abundance of beneficial gut bacteria and change the gut microbiota composition. The compound and composition of the invention can be applied in food, medicine, feed, nutritional supplements and other uses.

The invention discloses a screening and expression platform construction method for non-essential gene loci of corynebacterium glutamicum, and belongs to the technical field of biology. The center sites CGLRS02940, CGLRS03085, CGLRS08555, CGLRS09020 and CGLRS13560 of the corynebacterium glutamicum identified by the invention have the remarkable advantages that when gene knockout or knockin operation is carried out, the sites do not interfere with the normal physiological metabolism process of strains, and stable expression of exogenous genes can be guaranteed; meanwhile, the gene editing efficiency is relatively high, and an editing target with high universality and high reliability is provided for genetic engineering modification of corynebacterium glutamicum.

This invention belongs to the field of intestinal microbiome technology, specifically relating to a capsular polysaccharide derived from Bacteroides salorlis CSP6, its preparation method, and its applications. The monosaccharide composition of the capsular polysaccharide is mainly composed of fucose, glucose, and glucosamine, with a molecular weight of 7.139 × 10⁻⁶. 5 The strain described is deposited at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M20221993. In vitro studies have found that the capsular polysaccharide derived from Bacteroides Salieris CSP6 can inhibit α-glucosidase; in vivo animal experiments have demonstrated that this capsular polysaccharide can inhibit the rise in postprandial blood glucose and has a hypoglycemic effect.

The invention discloses a strain of Bacteroides ovatus L2 and application of the strain of Bacteroides ovatus L2 in a product for preventing and treating vomitoxin toxicity. The strain is preserved in Guangdong Microbiological Culture Collection Center, the preservation number is GDMCC.No: 67205, and the preservation date is November 4, 2025. The strain is separated and purified from a healthy adult excrement sample, has the characteristics of good acid resistance, cholate resistance, gastrointestinal fluid resistance and the like, and is free of hemolysis and good in safety. The strain can effectively relieve the toxic effect induced by vomitoxin, mainly inhibits inflammatory factors and promotes expression of intestinal barrier functional proteins, can be applied to products of microecologics for preventing and treating DON toxicity, and has a good application prospect.

The present application belongs to the field of microbial technology, and particularly relates to a bacteriophage preparation for controlling foodborne enterobacter and application thereof, wherein the bacteriophage preparation comprises any one or several of bacteriophage PhiEAS1, bacteriophage PhiEHO11, bacteriophage PhiEHO14 and bacteriophage PhiECL22. The four bacteriophages provided by the present application can be used alone or combined into a bacteriophage cocktail, and the influence of the bacteriophage preparation on enterobacter in different ecologies and environments is explored through bacteriophage cocktail therapy. The results show that the bacteriophage preparation exhibits significant bacteriostatic activity on various food substrates contaminated by Enterobacter hormaechei, such as lettuce, pork, milk, cherry tomato and the like; in an animal model, intraperitoneal injection of the bacteriophage preparation can effectively prevent and treat bacteremia caused by Enterobacter hormaechei, and shows potential as an anti-Enterobacter hormaechei biological control agent.

The invention belongs to the technical field of beverage mixing equipment, and particularly discloses a bifidobacterium beverage for regulating intestinal flora and mixing equipment, the bifidobacterium beverage comprises a bifidobacterium microbial inoculum, prebiotics, a base material and water; the equipment comprises a mixing tank, a rotating frame is rotationally arranged in the mixing tank, rotating blades are rotationally arranged on the rotating frame in the radial direction, a fixing shaft is arranged in the mixing tank, an end face fluted disc is arranged on the fixing shaft, and the ends, facing the center of the fixing shaft, of the rotating blades are meshed with the end face fluted disc; when the rotating frame rotates, the rotating blades synchronously rotate, and the composite motion of the rotating blades can fully cover conical areas at the upper end and the lower end of the mixing tank, so that a material deposition layer is effectively broken, and the problem of non-uniform component distribution caused by mixing dead angles of existing equipment is solved; meanwhile, the motion mode of composite stirring is milder, the local shear force can be obviously reduced, the inactivation of bifidobacterium cells due to mechanical damage is avoided, and the mixing efficiency and bacterial activity protection are both considered.

The invention discloses a novel acinetobacter baumannii phage vBAbaMpha0264 and application thereof, and belongs to the technical field of microorganisms. The acinetobacter baumannii phage vBAbaMpha0264 is preserved in the Guangdong Microbiological Culture Collection Center on August 28, 2025, the preservation number of the acinetobacter baumannii phage vBAbaMpha0264 is GDMCC (China General Microbiological Culture Collection Center) NO: 66893-B1, and the preservation address of the acinetobacter baumannii phage vBAbaMpha0264 is Institute of Microbiology, Academy of Sciences, Guangdong. The bacteriophage vBAbaMpha0264 has high cracking activity, environmental stability and safety, shows a breakthrough host range, and can be used for effectively cracking a plurality of acinetobacter bacteria including hospital acinetobacter and acinetobacter sysei. Meanwhile, the bacteriophage has excellent chloroform tolerance, and the stability of the bacteriophage is obviously superior to that of the existing bacteriophage. Due to the characteristics, the phage vBAbaMpha0264 overcomes the technical prejudice of'narrow spectrum and instability 'of the traditional phage, and a brand new technical scheme is provided for developing a universal antibacterial preparation covering more pathogenic bacteria.

The invention discloses bifidobacterium longum subsp. Infantis for regulating intestinal motility and aquaporin and application of the bifidobacterium longum subsp. Infantis, and belongs to the technical field of microorganisms. According to the invention, the bifidobacterium longum subsp. Infantis CCFM1269 is screened, and the bifidobacterium longum subsp. Infantis CCFM1269 has the effects of intestinal motility and aquaporin, specifically, the defecation frequency is reduced, and the water content of excrement and the small intestine propulsion rate are reduced. The intestinal motility abnormality is relieved by reducing the levels of neurotransmitters 5-HT, SP and VIP, and the intestinal moisture absorption and secretion are regulated by improving the mRNA expression of aquaporin AQP4 and AQP8. Meanwhile, the intestinal flora is adjusted by improving the diversity of the intestinal flora, and the content of propionic acid and butyric acid in excrement is increased.

The invention belongs to the technical field of medicines, and particularly relates to an aryl dicarboxylic acid compound, a preparation method and application of the aryl dicarboxylic acid compound as an antibacterial agent. The compound is shown as a formula (1), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are independently selected from hydrogen and halogen. Two ends of the molecule are connected through an N-phenylpropanamide connecting arm, the molecule is a compound with a novel structure, and the series of compounds have a relatively strong inhibition effect on acinetobacter baumannii and are worthy of further research and development.

This invention discloses a strain of *Bifidobacterium pseudosporidis*, its preparation method, and its application in the prevention and treatment of METH addiction. *Bifidobacterium pseudosporidis* was isolated from fecal samples of individuals with low levels of METH addiction, and its strain identity was confirmed after isolation, purification, and identification. A METH addiction model was constructed by gavage colonization of C57 mice with this strain, and addiction-related indicators were detected in the model mice. The results showed that compared with the addiction model mice without colonization of this strain, the conditioned place preference score of the colonized group was significantly reduced (P<0.05). This *Bifidobacterium pseudosporidis* has a significant effect on improving METH addictive behavior and can be used to prepare biological agents with preventive and / or therapeutic functions for METH addiction. This invention reveals that *Bifidobacterium pseudosporidis* has the advantages of high safety and strong targeting, and can achieve the prevention and intervention of METH addiction without complex treatment equipment, providing a novel biological treatment option for the clinical treatment of METH addiction.